Common use of Input Clause in Contracts

Input. MYLAN shall regularly advise THERAVANCE of the status of all MYLAN Product Patents and, at THERAVANCE's request, shall provide THERAVANCE with copies of all documentation concerning MYLAN Product Patents, including all correspondence to and from any Governmental Authority. Prior to filing patent applications or significant prosecution documents relating to MYLAN Product Patents, MYLAN shall solicit THERAVANCE's advice on the content of the patent application or prosecution document and MYLAN shall take into account THERAVANCE's reasonable comments related thereto, unless (without fault of MYLAN) deadlines will not permit such review or THERAVANCE notifies MYLAN that it does not wish to review such documents. In the event of a dispute between the Parties regarding the content of patent applications or prosecution documents, MYLAN shall have the final decision-making authority with respect to any action relating to MYLAN Product Patents subject to the provisions of Section 12.02(e) or Section 12.02(h), although THERAVANCE and MYLAN shall seek to agree on which Countries in the Territory in which MYLAN Product Patents shall be filed within the priority period and the content of patent applications or prosecution documents with respect to the MYLAN Product Patents.

Input. MYLAN THERAVANCE shall regularly advise THERAVANCE MYLAN of the status of all MYLAN Product THERAVANCE Patents andin the Territory, at THERAVANCE's request, and shall provide THERAVANCE MYLAN with copies of all material documentation concerning MYLAN Product PatentsTHERAVANCE Patents in the Territory, including all correspondence to and from any Governmental Authority. Prior to filing new THERAVANCE Patents, including patent applications claiming THERAVANCE Inventions, or significant prosecution documents relating to MYLAN Product PatentsTHERAVANCE Patents in the Territory, MYLAN THERAVANCE shall solicit THERAVANCEMYLAN's advice on the content of the patent application or prosecution document and MYLAN THERAVANCE shall take into account THERAVANCEand incorporate MYLAN's reasonable comments related thereto, unless (without fault of MYLANTHERAVANCE) deadlines will not permit such review or MYLAN notifies THERAVANCE notifies MYLAN that it does not wish to review such documents. In the event of a dispute between the Parties regarding the content of patent applications or prosecution documents, MYLAN THERAVANCE shall have the final decision-making authority with respect to any action relating to MYLAN Product Patents claiming THERAVANCE Inventions or THERAVANCE Patents, subject to the provisions of Section 12.02(e12.02(d) or Section 12.02(h), although THERAVANCE and MYLAN shall seek to agree on which Countries in the Territory in which MYLAN Product THERAVANCE Patents shall be filed within the priority period and the content of patent applications or prosecution documents with respect to the MYLAN Product Patentsdocuments.

Input. MYLAN shall regularly advise THERAVANCE of the status of all MYLAN Product Patents and, at THERAVANCE's ’s request, shall provide THERAVANCE with copies of all documentation concerning MYLAN Product Patents, including all correspondence to and from any Governmental Authority. Prior to filing patent applications or significant prosecution documents relating to MYLAN Product Patents, MYLAN shall solicit THERAVANCE's ’s advice on the content of the patent application or prosecution document and MYLAN shall take into account THERAVANCE's ’s reasonable comments related thereto, unless (without fault of MYLAN) deadlines will not permit such review or THERAVANCE notifies MYLAN that it does not wish to review such documents. In the event of a dispute between the Parties regarding the content of patent applications or prosecution documents, MYLAN shall have the final decision-making authority with respect to any action relating to MYLAN Product Patents subject to the provisions of Section 12.02(e) or Section 12.02(h), although THERAVANCE and MYLAN shall seek to agree on which Countries in the Territory in which MYLAN Product Patents shall be filed within the priority period and the content of patent applications or prosecution documents with respect to the MYLAN Product Patents.

Input. MYLAN THERAVANCE shall regularly advise THERAVANCE MYLAN of the status of all MYLAN Product THERAVANCE Patents andin the Territory, at THERAVANCE's request, and shall provide THERAVANCE MYLAN with copies of all material documentation concerning MYLAN Product PatentsTHERAVANCE Patents in the Territory, including all correspondence to and from any Governmental Authority. Prior to filing new THERAVANCE Patents, including patent applications claiming THERAVANCE Inventions, or significant prosecution documents relating to MYLAN Product PatentsTHERAVANCE Patents in the Territory, MYLAN THERAVANCE shall solicit THERAVANCE's MYLAN’s advice on the content of the patent application or prosecution document and MYLAN THERAVANCE shall take into account THERAVANCE's and incorporate MYLAN’s reasonable comments related thereto, unless (without fault of MYLANTHERAVANCE) deadlines will not permit such review or MYLAN notifies THERAVANCE notifies MYLAN that it does not wish to review such documents. In the event of a dispute between the Parties regarding the content of patent applications or prosecution documents, MYLAN THERAVANCE shall have the final decision-making authority with respect to any action relating to MYLAN Product Patents claiming THERAVANCE Inventions or THERAVANCE Patents, subject to the provisions of Section 12.02(e12.02(d) or Section 12.02(h), although THERAVANCE and MYLAN shall seek to agree on which Countries in the Territory in which MYLAN Product THERAVANCE Patents shall be filed within the priority period and the content of patent applications or prosecution documents with respect to the MYLAN Product Patentsdocuments.